These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36977709)

  • 1. A novel model of the continual reassessment method in Phase I trial.
    Zhang W; Lei W; Zhu X
    Sci Rep; 2023 Mar; 13(1):5047. PubMed ID: 36977709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
    Chiuzan C; Dehbi HM
    Clin Trials; 2024 Jun; 21(3):350-357. PubMed ID: 38618916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of two-stage continual reassessment method relative to an optimal benchmark.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay of priors and skeletons in two-stage continual reassessment method.
    Iasonos A; O'Quigley J
    Stat Med; 2012 Dec; 31(30):4321-36. PubMed ID: 22893483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
    Zohar S; Chevret S
    Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
    Chen X; Zhang J; Jiang Q; Yan F
    J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2021 Apr; 40(8):2073-2082. PubMed ID: 33588519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
    Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
    Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
    Zhou H; Yuan Y; Nie L
    Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simulation-free approach to assessing the performance of the continual reassessment method.
    Braun TM
    Stat Med; 2020 Dec; 39(30):4651-4666. PubMed ID: 32939800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the dose-toxicity curve in completed phase I studies.
    Iasonos A; Ostrovnaya I
    Stat Med; 2011 Jul; 30(17):2117-29. PubMed ID: 21341302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continual reassessment method with regularization in phase I clinical trials.
    Li X; Ivanova A; Tian H; Lim P; Liu K
    J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.